2) Diagnostic PET/SPECT【Oncology PET】
PSMA-PET clinical research in prostate cancer
F-18 PSMA-1007 PET, which is a state-of-the-art diagnostic imaging for detecting prostate cancer recurrence and metastasis with high accuracy, was launched in September 2019 for the first time in Japan.
It has been found that PSMA-PET can detect recurrent / metastatic lesions which conventional diagnostic imaging (CT and bone scintigraphy) failed to detect.
The PSMA-PET agent (F-18 PSMA-1007 injection) has been successfully manufactured using a synthesizer (manufactured by Sumitomo Heavy Industries, Ltd.).
PSMA is also effective as a treatment target in prostate cancer, and labeling with a therapeutic nuclide can have a significant therapeutic effect on advanced cancer. It is expected to expand to treatment in Japan in the future.